Novartis to Invest US$23 Billion in Denton, Texas, USA
Introduction:
Novartis has announced plans to invest US$23 billion to establish a new radioligand therapy manufacturing facility in Denton, Texas.
Features:
The project involves the construction of a 46,000-square-foot radioligand therapy manufacturing facility dedicated to the production of radiopharmaceuticals for cancer treatment.
The facility will manufacture radioligand therapy medicines, including the preparation of patient-specific doses that require rapid production and distribution due to the short half-life of radioactive isotopes. Manufacturing operations will include radiolabelling, quality control, packaging and time-sensitive distribution.
The facility is designed to support the manufacture of radioligand therapies for a range of oncology indications. The development includes specialised production areas, controlled environments and radiation safety systems required for the handling and processing of radioactive materials.
The project forms part of the expanding radiopharmaceutical manufacturing sector, where rapid production, quality assurance and efficient distribution are essential to ensure timely delivery of therapies to hospitals and treatment centres.
Construction is scheduled to begin this year, with the facility expected to become operational in 2028.
Specifications:
| Name | Novartis |
| Type | New Construction |
| Budget | US$23 billion |
| Year | 2028 |
